# Intelligent Bio Solutions Revenue Rises 25% to Record $1.39 Million in Fiscal Q1

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54376
Published: 2026-11-11T19:43:37.000Z
Updated: 2026-11-11T19:43:37.000Z
Section: Business

> Net loss narrowed to $2.67 million. Management expects its Sept. 30 cash balance to be insufficient for its operating plan for at least 12 months from the statements’ issuance and says additional funds will be needed.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) posted a 25% increase in fiscal first-quarter 2027 revenue to a record $1.39 million, while management expects its cash balance to be insufficient for its operating plan.

Revenue was $1,391,835 for the three months ended Sept. 30, up from the year-ago quarter. It was the company’s third consecutive quarter with revenue above $1 million.

Net loss narrowed to $2,668,435 from $2,994,992 a year earlier. Basic and diluted loss per share was $0.86, compared with $3.49 in the prior-year quarter. The weighted-average share count used to calculate the per-share result rose to 3,095,306 from 854,693.

Gross profit increased to $758,004 from $518,291. Gross margin was 54.5%, up from 46.6% a year earlier.

Intelligent Bio Solutions develops noninvasive testing products, including a drug-screening system that analyzes sweat from fingerprints.

The company had $5,929,871 in cash and cash equivalents on Sept. 30. Management expects the Sept. 30 cash balance to be insufficient to fund the current operating plan for at least 12 months from the statements’ issuance and says additional funds will be needed during that period. The projected need for additional funds raises substantial doubt about whether Intelligent Bio Solutions can continue as a going concern.